Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Atrial fibrillation is a type of cardiac arrhythmia distinguished by an abnormal cardiac rhythm caused by a disturbance in heart’s electrical system. It is considered to be one of the most prevalent types of cardiac arrhythmia. General symptoms associated with atrial fibrillation include, fluttering heartbeat, irregular pulse, weakness, dizziness, and fatigue.

Statistics:

The global atrial fibrillation market is estimated to account for US$ 40,601.7 Mn in terms of value by the end of 2027.

Global Atrial Fibrillation Market: Drivers

High prevalence of atrial fibrillation is expected to propel growth of the global atrial fibrillation market over the forecast period. For instance, according to the study ‘Prevalence of atrial fibrillation (AF) in different socioeconomic regions of China and its association with stroke: Results from a national stroke screening survey’, published in June 2018, the prevalence of AF among Chinese adults aged 40 years in 2014–2015 was 2.31%.

Moreover, increasing geriatric population is also expected to aid in growth of the global atrial fibrillation market. For instance, according to the World Health Organization, geriatric population is expected to reach 2 billion by 2050, up from 900 million in 2015.   

Statistics:

North America held dominant position in the global atrial fibrillation market in 2019, accounting for 43.4% share in terms of value, followed by Europe and Asia Pacific, respectively.

Figure 1: Global Atrial Fibrillation Market Share (%) Value, By Region, 2019

Atrial Fibrillation  | Coherent Market Insights

Global Atrial Fibrillation Market: Restraints

Stringent product approval regulations are expected to hinder growth of the global atrial fibrillation market. Atrial fibrillation devices such as implantable pacemakers, defibrillators, and catheters are regarded as class III high risk medical devices by the U.S. FDA. Therefore, these devices undergo rigorous safety and efficacy tests prior to receiving an approval. Moreover, these devices also need to obtain a premarket approval which is an expensive and lengthy affair.

Moreover, recall of products is also expected to hinder growth of the global atrial fibrillation market. For instance, in February 2019, Medtronic Plc received FDA product recall for implanted cardiac pacemakers, which affected 13,440 devices manufactured and distributed between March 2017 and January 2019.

request-sample

Atrial Fibrillation Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 14,804.5 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 13.4% 2027 Value Projection: US$ 40,601.7 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
  • Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: North Africa, Central Africa, South Africa
Segments covered:
  • By Procedure:
    • Pharmacological: Anti-arrhythmic, Anti-coagulant.
    • Non-Pharmacological: Catheter Ablation Procedures, Maze surgery, Electric Cardioversion.
Companies covered:

AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Johnson and Johnson Ltd., and Abbott Laboratories.

Growth Drivers:
  • Increasing prevalence of atrial fibrillation
  • Approval and launch of new products
Restraints & Challenges:
  • Product recall
  • Stringent Regulation

Global Atrial Fibrillation Market: Opportunities

Use of Artificial Intelligence (AI) in diagnosis of atrial fibrillation is expected to offer lucrative growth opportunities for players in the global atrial fibrillation market. For instance, in August 2019, a team of researchers from Mayo Clinic reported development of a rapid, AI-based test that can identify patients with an abnormal heart rhythm, in the journal The Lancet.

Moreover, high prevalence of atrial fibrillation in athletes is also expected to aid in growth of the market. For instance, in July 2019, researchers from Miller Family Heart and Vascular Institute at the Cleveland Clinic reported in the Journal of the American Heart Association that retired NFL players were five times more likely to have atrial fibrillation.

Statistics:

The global atrial fibrillation market was valued at US$ 14,804.5 Mn in 2019 and is forecast to reach a value of US$ 40,601.7 Mn by 2027 at a CAGR of 13.4% between 2020 and 2027.

Figure 2: Global Atrial Fibrillation Market Value (US$ Mn), 2016 – 2027

Atrial Fibrillation  | Coherent Market Insights

Market Trends/Key Takeaways

High prevalence of obesity is expected to propel growth of the global atrial fibrillation market over the forecast period. For instance, the study, ‘Rising incidence of obesity in Saudi residents. A threatening challenge for the surgeons’, published in the International Journal of Health Sciences, in January 2018, reported obesity in 42% of the study population with low physical activity levels and unhealthy dietary habits.

 Moreover, high consumption of alcohol is also expected to aid in growth of the market. For instance, according to the 2018 National Survey on Drug Use and Health, in the U.S., around 164.8 million people aged 12 or older in the U.S. were past month substance users that included tobacco, alcohol, or illicit drugs.

Global Atrial Fibrillation Market: Competitive Landscape

Major players operating in the global atrial fibrillation market include, AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Inc., Johnson and Johnson Ltd., and Abbott Laboratories.

Global Atrial Fibrillation Market: Key Developments

Major players in the global atrial fibrillation market are focused on approval and launch of new devices to expand their product portfolio. For instance, in May 2020, CardioFocus, Inc. received the U.S. Food and Drug Administration approval for the next-generation HeartLight X3 Endoscopic Ablation System for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation.

Atrial Fibrillation is also known as A-fib or AF, is an irregular heartbeat exemplified by rapid and abnormal beating of the heart. It is linked with an elevated risk of heart failure, stroke, and dementia. Atrial fibrillation is a type of cardiac arrhythmia distinguished by an abnormal cardiac rhythm caused by a disturbance in heart’s electrical system. High prevalence of atrial fibrillation along with increasing product approvals during the forecasted period is expected to assist the growth of the market. Furthermore, major players in the global atrial fibrillation market are focused on R&D to expand their product portfolio which is also expected to drive the market during the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the Global Atrial Fibrillation market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the Global Atrial Fibrillation market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Inc., Johnson and Johnson Ltd., and Abbott Laboratories.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The Global Atrial Fibrillation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Atrial Fibrillation market

Detailed Segmentation:

  • Global Atrial Fibrillation Market, By Procedure:
    • Pharmacological
      • Anti-arrhythmic
      • Anti-coagulant
    • Non-Pharmacological
      • Catheter Ablation Procedures
      • Maze surgery
      • Electric Cardioversion
  • Global Atrial Fibrillation Market, By Region:
    • North America
      • By Procedure:
        • Pharmacological
          • Anti-arrhythmic
          • Anti-coagulant
        • Non-Pharmacological
          • Catheter Ablation Procedures
          • Maze surgery
          • Electric Cardioversion
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Procedure:
        • Pharmacological
          • Anti-arrhythmic
          • Anti-coagulant
        • Non-Pharmacological
          • Catheter Ablation Procedures
          • Maze surgery
          • Electric Cardioversion
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Procedure:
        • Pharmacological
          • Anti-arrhythmic
          • Anti-coagulant
        • Non-Pharmacological
          • Catheter Ablation Procedures
          • Maze surgery
          • Electric Cardioversion
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Procedure:
        • Pharmacological
          • Anti-arrhythmic
          • Anti-coagulant
        • Non-Pharmacological
          • Catheter Ablation Procedures
          • Maze surgery
          • Electric Cardioversion
      • By Country
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Procedure:
        • Pharmacological
          • Anti-arrhythmic
          • Anti-coagulant
        • Non-Pharmacological
          • Catheter Ablation Procedures
          • Maze surgery
          • Electric Cardioversion s
      • By Country
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • By Procedure:
        • Pharmacological
          • Anti-arrhythmic
          • Anti-coagulant
        • Non-Pharmacological
          • Catheter Ablation Procedures
          • Maze surgery
          • Electric Cardioversion
      • By Country
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • AtriCure, Inc. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Biosense Webster, Inc.
    • Boehringer Ingelheim GmbH
    • Boston Scientific Corporation
    • Bristol-Myers Squibb Corporation
    • CardioFocus, Inc.
    • Endoscopic Technologies, Inc.
    • Sanofi Aventis, Inc.
    • Johnson and Johnson Ltd.
    • Abbott Laboratories
  •  “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Procedure
      • Market Snippet, By Country
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • PEST Analysis
    • Technological Advancements
    • Regulatory Scenario
    • Mergers and Acquisitions
  4. Global Atrial Fibrillation Market, By Procedure, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Pharmacological
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Anti-arrhythmic
        • Anti-coagulant
    • Non-Pharmacological
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Catheter Ablation Procedures
        • Maze surgery
        • Electric Cardioversion
  5. Global Atrial Fibrillation Market, By Region, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Procedure, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Procedure, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Procedure, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Procedure, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Procedure, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Procedure, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  6. Competitive Landscape
    • Company Profiles
      • AtriCure, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Biosense Webster, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Boston Scientific Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol-Myers Squibb Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CardioFocus, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Endoscopic Technologies, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi Aventis
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson and Johnson Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  7. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 22 market data tables and 14 figures on “Atrial Fibrillation Market - Global forecast to 2027”.

Frequently Asked Questions

The Global Atrial Fibrillation Market size was valued at US$ 14,804.5 million in 2019 and is estimated to exhibit a CAGR of 13.4% between 2020 and 2027.
Pharmacological segment held the major market share in 2019 owing to an increasing prevalence of atrial fibrillation is expected to propel growth of the market.
Major factor driving the growth of Global Atrial Fibrillation Market during the forecast period prevalence of atrial fibrillation, increasing product approval, increasing research & development , and adoption of expansion strategies from major companies.
Major factors hampering the growth of the Global Atrial Fibrillation Market during the forecast period constitutes of stringent regulatory landscape.
North America market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Johnson and Johnson Ltd., and Abbott Laboratories.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner